In This Section

An Apel(-in) a Day Keeps Cardiovascular Disorders at Bay?

Saturday April 06, 2019

11:00 am - 1:00 pm Eastern Time (ET)

Room W206 A


Chair :

Hyung Chun
Yale University

Rangan Maitra
RTI International

The apelin receptor system has recently emerged as an exciting new drug target. Come learn about the fascinating journey of this GPCR from the bench to the bedside at this symposium. The apelin receptor is an important player in various types of cardiovascular diseases including heart failure, metabolic syndrome and preeclampsia. Major pharmaceutical companies have recently initiated clinical trials targeting this receptor system. An international panel of experts will present cutting-edge research from their laboratories with an eye on drug development using peptides and small molecules.


Hyung Chun - Yale University

Cardiometabolic Role of APJ

Bruno Reversade - Institute of Molecular and Cellular Biology, A*STAR, Singapore

The Elabela-Ergic Pathway: From Pluripotency to Preeclampsia

Rangan Maitra - RTI International

Biased APJ Ligands for Heart Failure

Isabelle Castan-Laurell - INSERM U1048 I2MC

The Apelinergic System in Type 2 Diabetes: From Bench to Bedside

Liliya Yamaleyeva - Wake Forest University School of Medicine

Hemodynamic Effects of Apelin in Preeclampsia

Carl White - University of Nottingham

Using CRISPR/Cas9 and NanoLuc to Investigate ‘Endogenous’ CXCR4 Ligand Binding, Internalisation and β-arrestin2 Recruitment

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019